Dipexium Pharmaceuticals Now Covered by Analysts at Feltl & Co. (DPRX)
Analysts at Feltl & Co. initiated coverage on shares of Dipexium Pharmaceuticals (NASDAQ:DPRX) in a research report issued to clients and investors on Wednesday, TheFlyOnTheWall.com reports. The firm set a “strong-buy” rating on the stock.
Dipexium Pharmaceuticals (NASDAQ:DPRX) traded down 0.23% on Wednesday, hitting $8.8799. 36,860 shares of the company’s stock traded hands. Dipexium Pharmaceuticals has a 52 week low of $8.00 and a 52 week high of $15.86. The stock has a 50-day moving average of $9.62 and a 200-day moving average of $10.1. The company’s market cap is $51.1 million.
In other Dipexium Pharmaceuticals news, Director Jack H. Dean purchased 3,000 shares of the stock in a transaction dated Wednesday, May 21st. The stock was purchased at an average price of $9.00 per share, for a total transaction of $27,000.00. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
Several other analysts have also recently commented on the stock. Analysts at Zacks initiated coverage on shares of Dipexium Pharmaceuticals in a research note on Wednesday, April 16th. They set a “hold” rating on the stock. Analysts at Oppenheimer initiated coverage on shares of Dipexium Pharmaceuticals in a research note on Monday, April 7th. They set an “outperform” rating and a $27.00 price target on the stock.
Dipexium Pharmaceuticals, Inc, formerly Dipexium Pharmaceuticals, LLC, is a pharmaceutical company. The Company is focused on the development and commercialization of Locilex.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.